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Polymorphisms of the matrix 
metalloproteinase genes are 
associated with essential 
hypertension in a Caucasian 
population of Central Russia
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This study aimed to determine possible association of eight polymorphisms of seven MMP genes 
with essential hypertension (EH) in a Caucasian population of Central Russia. Eight SNPs of the 
MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, and MMP12 genes and their gene–gene (epistatic) 
interactions were analyzed for association with EH in a cohort of 939 patients and 466 controls using 
logistic regression and assuming additive, recessive, and dominant genetic models. The functional 
significance of the polymorphisms associated with EH and 114 variants linked to them  (r2 ≥ 0.8) was 
analyzed in silico. Allele G of rs11568818 MMP7 was associated with EH according to all three genetic 
models (OR = 0.58–0.70,  pperm = 0.01–0.03). The above eight SNPs were associated with the disorder 
within 12 most significant epistatic models (OR = 1.49–1.93,  pperm < 0.02). Loci rs1320632 MMP8 
and rs11568818 MMP7 contributed to the largest number of the models (12 and 10, respectively). 
The EH-associated loci and 114 SNPs linked to them had non-synonymous, regulatory, and eQTL 
significance for 15 genes, which contributed to the pathways related to metalloendopeptidase 
activity, collagen degradation, and extracellular matrix disassembly. In summary, eight studied SNPs 
of MMPs genes were associated with EH in the Caucasian population of Central Russia.
Cardiovascular diseases are a global problem of modern healthcare and the second most common cause of total 
 mortality1,2. Among cardiovascular diseases, essential hypertension (EH) is of tremendous clinical importance 
in terms of health, working capacity, and life  expectancy3–5. According to some estimates, the number of patients 
with EH will reach 1.56 billion by  20256. More than 9.4 million death cases resulting from EH complications, 
such as stroke, myocardial infarction, renal failure, etc., are recorded worldwide  annually7–9.
The development of EH is determined by complex interaction mechanisms of genetic and environmental 
 factors5,10–12. The contribution of hereditary factors to EH is estimated from 25 to 75% in different populations 
according to family and twin  studies13,14. Among the possible candidate genes for EH are matrix metallopro-
teinases (MMP). This is a group of enzymes with a wide range of biological functions that are responsible 
for the hydrolysis of the extracellular matrix (ECM)  components15–18. The imbalance between synthesis and 
degradation of ECM caused by the change in MMP gene expression can lead to a decrease in the ability of 
the vascular wall to remodel and to the development of cardiovascular  diseases19,20. It was found that single 
nucleotide polymorphisms (SNP) of the MMP genes are associated with EH and its complications in different 
populations: Australian (rs3025058 MMP3), Polish (rs3025058 MMP3), American (rs652438 MMP12), Swed-
ish (rs11568818 MMP7), Brazilian (rs243865 MMP2), Serbian (rs11225395 and rs1320632 MMP8, rs1799750 
MMP1) and  others16,19,21–26. However, no associations of the MMP polymorphisms with EH and its complica-
tions were found in Chinese (rs3025058 MMP3, rs17577 MMP9), Indian (rs11568818 MMP7), and Mexican 
(rs1799750 MMP1)  populations27–29. The observed inconsistencies prompt for further studies of the role of the 
MMP polymorphisms in the development of EH.
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In this study, we analyzed the associations of matrix metalloproteinases and their gene–gene interactions with 
EH in a Caucasian population of Central Russia. We also examined the biological mechanisms of their phenotypic 
effects and SNPs linked to them (nonsynonymous substitutions, regulatory and cis-eQTL influences, pathways).
Results
Study participants characteristics. The patients with EH had higher rates of BMI, total cholesterol, tri-
glycerides, low-density lipoprotein cholesterol, low high-density lipoprotein cholesterol, and a high incidence of 
smokers (p < 0.001) (Table 1). These factors were applied as covariates in the association analyses.
Analysis of SNP association. The data about the studied SNPs is given in Table 2. All loci had MAF > 5% 
and showed no departure from the HWE (p > 0.05).
The allele G of the rs11568818 MMP7 polymorphism was associated with EH according to the additive 
(OR = 0.70, 95% CI 0.54–0.89, p = 0.001,  pperm = 0.01, power 99.03%), dominant (OR = 0.66, 95% CI 0.46–0.97, 
p = 0.02,  pperm = 0.03, power 94.50%) and recessive (OR = 0.58, 95% CI 0.37–0.91, p = 0.01,  pperm = 0.02, power 
91.54%) models (Table 3).
SNP × SNP interactions. In total 12 most significant two-, three, and four-locus models of gene–gene 
interactions associated with EH were determined  (pperm ≤ 0.02, cross-validation consistency CVC = 10/10, test-
ing balanced accuracy 49.2–55.3%) (Tables 4 and 5). These models included eight SNPs. Loci rs1320632 MMP8 
and rs11568818 MMP7 were involved in the largest number of models (12 and 10, respectively). Loci rs652438 
MMP12, rs11225395 MMP8, rs1320632 MMP8, and rs11568818 MMP7 contributed to the most significant 
epistatic models  (pperm = 0.002). The following combinations of genotypes had most significant associations with 
EH: rs11225395 CT × rs1320632 AG × rs11568818 CC (beta = −  0.827, p = 0.002), rs652438 AA × rs11225395 
CT × rs1320632 AG × rs11568818 CT (beta = −  0.847, p = 0.003), rs17577 AG × rs1320632 AG × rs11568818 
CT × rs1799750 1G/1G (beta = − 1.726, p = 0.002) (Supplementary Table   1).
The graph of the most significant epistatic models of the four SNPs (Fig. 1) suggests these interactions are 
concerted. Pronounced synergism was observed between the polymorphisms of the MMP8 gene, while an 
antagonistic interaction was suggested between rs652438 MMP12 and rs11568818 MMP7. The graph of interac-
tions (Fig. 1b) shows that rs11225395 MMP8 and rs11568818 MMP7 eliminated 0.34 and 0.25% of class entropy, 
respectively, thereby having the largest univariate effects.
Functional SNP. Non‑synonymous SNPs. Among the eight SNPs studied, two loci (rs17577 MMP9 and 
rs652438 MMP12) cause the replacement of amino acids in the encoded polypeptide and a decrease in its activ-
ity (Supplementary Table 2). Also, three non-synonymous variants (rs679620 MMP3, rs1940475 and rs3765620 
MMP8) were determined among the polymorphisms linked to the studied SNPs (Supplementary Table 2).
Regulatory effects. The data on the regulatory effects of the EH-associated loci are presented in Supplemen-
tary Table 3. According to the HaploReg database (v4.1), two SNPs were located in evolutionarily conserved 
regions, two polymorphisms—in the promoter histone marks region, and eight SNPs—in the enhancer histone 
marks region in various tissues. Seven SNPs were in the hypersensitivity region to DNAse-1, three SNPs—in the 
protein-bound region, five SNPs—in the motifs changed region. According to the SNPinfo Web Server database, 
polymorphisms rs1320632 MMP8 and rs11225395 MMP8 possessed the most significant regulatory potential 
(0.53 and 0.20, respectively). Four SNPs were located in the regions of the transcription factor binding site 
Table 1.  Phenotypic characteristics of the study participants. Clinical characteristics of age, BMI, SBP, DBP, 
HDL-C, LDL-C, TG and TC are given as means ± SD and other values as number of individuals. BMI, body 
mass index, SBP, systolic blood pressure, DBP, diastolic blood pressure; TC, total cholesterol, HDL‑C, high-
density lipoprotein cholesterol, TG, triglycerides, LDL‑C, low-density lipoprotein cholesterol.
Parameters EH, mean ± SD, % (n) Controls, mean ± SD, % (n) p
N 939 466 –
Gender (male/female) 60.06 /39.94 (564/375) 55.15/44.85 (257/209) 0.09
Age (years) 58.08 ± 8.91 57.82 ± 9.52 0.77
BMI (kg/m2) 30.78 ± 5.08 24.94 ± 3.14 < 0.001
SBP (mmHg) 182.48 ± 28.26 122.58 ± 11.49 < 0.001
DBP (mmHg) 105.84 ± 13.47 77.65 ± 6.93 < 0.001
TC (mM) 5.71 ± 1.29 5.26 ± 1.04 < 0.001
HDL-C (mM) 1.34 ± 0.42 1.52 ± 0.42 < 0.001
LDL-C (mM) 3.78 ± 1.11 3.22 ± 0.74 < 0.001
TG (mM) 1.92 ± 1.03 1.22 ± 0.71 < 0.001
Blood glucose (mM) 5.92 ± 1.68 4.88 ± 0.95 < 0.001
Smoking 38.33 (353) 19.76 (84) < 0.001
Alcohol abuse 5.79 (53) 3.12 (13) 0.051
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(TFBS), one was in the microRNA binding region, and two were in the exonic splicing enhancer and exonic 
splicing silencer. SNP rs11568818 was located in the DNA regulatory motifs region: the allele G increased affinity 
to transcription factors Foxa (ΔLOD scores = − 5.1), PLZF (ΔLOD scores = − 1.5), Pou5f1 (ΔLOD scores = − 3.2) 
and reduced affinity to GR transcription factor (ΔLOD scores = 0.8).
In addition to the eight EH-associated SNPs, regulatory significance was estimated for 114 polymorphisms 
linked to them (Supplementary Table 4). Eight SNPs (including five non-synonymous and three synonymous 
substitutions) were located in exons of the studied genes, three were located in 3′-UTR and one in 5′-UTR, 86 
were in introns, and 44 were in intergenic regions. Nine loci were located in evolutionarily conserved regions.
The in silico analysis of SNPs linked to the EH-associated loci suggested several polymorphisms with pro-
nounced regulatory effects (Supplementary Table 4). For example, rs243862 (linked to rs243865 MMP2) is located 
in the promoter histone marks region in 21 tissues and enhancer histone marks in two tissues, the hypersensitivity 
region to DNAse-1 in 19 tissues, region 14 motifs changed.
Table 2.  The allele and genotype frequencies (%) of the studied SNPs in the EH and control groups. The 
number in the brackets represents the number of participants with the respective genotype (or allele).
SNP Genotypes, indicators EH, % (n) Controls, % (n)
rs11568818 MMP7
AA 36.38 (338) 31.82 (147)
AG 48.65 (452) 49.13 (227)
GG 14.97 (139) 19.05 (88)
Minor allele G 39.29 (730) 43.61 (403)
Ho/He  (pHWE) 0.49/0.48 (p > 0.05) 0.49/0.49 (p > 0.05)
rs1320632 MMP8
AA 84.67 (784) 81.48 (374)
AG 14.47 (134) 17.65 (81)
GG 0.86 (8) 0.87 (4)
Minor allele G 8.10 (150) 9.69 (89)
Ho/He  (pHWE) 0.14/0.15 (p > 0.05) 0.18/0.17 (p > 0.05)
rs11225395 MMP8
CC 31.09 (291) 25.97 (120)
CT 48.50 (454) 48.27 (223)
TT 20.41 (191) 25.76 (119)
Minor allele T 44.66 (836) 49.89 (461)
Ho/He  (pHWE) 0.48/0.49 (p > 0.05) 0.48/0.50 (p > 0.05)
rs1799750 MMP1
1G/1G 28.01 (263) 28.73 (133)
1G/2G 49.20 (462) 47.30 (219)
2G/2G 22.79 (214) 23.97 (111)
Minor allele 2G 890 (47.39) 47.62 (441)
Ho/He  (pHWE) 0.49/0.50 (p > 0.05) 0.47/0.50 (p > 0.05)
rs3025058 MMP3
6A/6A 30.63 (287) 26.73 (127)
5A/6A 48.77 (457) 50.53 (240)
5A/5A 20.60 (193) 22.74 (108)
Minor allele 5A 44.98 (843) 48.00 (456)
Ho/He  (pHWE) 0.48/0.50 (p > 0.05) 0.51/0.50 (p > 0.05)
rs652438 MMP12
AA 86.97 (814) 90.20 (414)
AG 12.39 (116) 9.37 (43)
GG 0.64 (6) 0.43 (2)
Minor allele G 128 (6.84) 5.12 (47)
Ho/He  (pHWE) 0.12/0.13 (p > 0.05) 0.09/0.10 (p > 0.05)
rs243865 MMP2
CC 58.15 (546) 59.57 (277)
CT 35.14 (330) 35.05 (163)
TT 6.71 (63) 5.38 (25)
Minor allele T 24.28 (456) 25.66 (213)
Ho/He  (pHWE) 0.35/0.37 (p > 0.05) 0.39/0.38 (p > 0.05)
rs17577 MMP9
GG 66.95 (622) 61.00 (280)
AG 29.82 (277) 34.64 (159)
AA 3.23 (30) 4.36 (20)
Minor allele A 18.14 (337) 21.68 (199)
Ho/He  (pHWE) 0.30/0.30 (p > 0.05) 0.35/0.34 (p > 0.05)
4
Vol:.(1234567890)
Scientific Reports |         (2021) 11:5224  | https://doi.org/10.1038/s41598-021-84645-4
www.nature.com/scientificreports/
Table 3.  Association of the MMPs genotypes with EH. OR odds ratio, 95% CI 95% confidence interval, p 
significance level.
SNPs Model Genotype OR (95% CI) p
rs11568818 MMP7
Dominant AG/GG vs AA 0.66 (0.46–0.97) 0.02
Recessive GG vs AG/AA 0.58 (0.37–0.91) 0.01
Additive AG vs GG vs AA 0.70 (0.54–0.89) 0.001
rs1320632 MMP8
Dominant GA/GG vs AA 0.66 (0.42–1.05) 0.07
Recessive GG vs GA/AA 0.84 (0.09–8.27) 0.99
Additive GA vs GG vs AA 0.69 (0.45–1.06) 0.08
rs11225395 MMP8
Dominant CT/TT vs CC 0.74 (0.50–1.10) 0.13
Recessive TT vs CT/CC 0.69 (0.46–1.04) 0.15
Additive CT vs TT vs CC CT vs TT vs CC 0.78 (0.61–1.00) 0.07
rs1799750 MMP1
Dominant 1G2G/2G2G vs 1G1G 1.07 (0.73–1.56) 0.71
Recessive 2G2G vs 1G2G /1G1G 1.02 (0.68–1.53) 0.86
Additive 1G2G vs 2G2G vs 1G1G 1.03 (0.81–1.31) 0.70
rs3025058 MMP3
Dominant 5A6A /5A5A vs 6A6A 1.12 (0.77–1.62) 0.61
Recessive 5A5A vs 5A6A/6A6A 0.87 (0.57–1.34) 0.69
Additive 5A6A vs 6A6A vs 5A5A 1.01 (0.79–1.28) 0.75
rs652438 MMP12
Dominant GA/GG vs AA 1.46 (0.81–2.61) 0.26
Recessive GG vs GA/AA 1.34 (0.10–1.74) 0.86
Additive GA vs GG vs AA 1.41 (0.81–2.44) 0.19
rs243865 MMP2
Dominant CT/TT vs CC 1.04 (0.73–1.48) 0.86
Recessive TT vs CT/CC 1.55 (0.71–3.39) 0.26
Additive CT vs TT vs CC 1.09 (0.82–1.46) 0.85
rs17577 MMP9
Dominant AG/AA vs GG 0.94 (0.66–1.35) 0.85
Recessive AA vs AG/GG 0.91 (0.36–2.32) 0.74
Additive AG vs GG vs AA 0.95 (0.69–1.29) 0.68
Table 4.  Gene–gene interactions significantly associated with the risk of EH according to MB-MDR. NH, 
number of significant High risk genotypes in the interaction, beta H, regression coefficient for High risk 
exposition in the step 2 analysis, NA – not available, WH, Wald statistic for High risk category, NL, number of 
significant Low risk genotypes in the interaction, beta L, regression coefficient for Low risk exposition in the 
step 2 analysis, WL, Wald statistic for Low risk category, Pperm, Permutation P-value for the interaction model.
N SNP x SNP interaction models NH betaH WH NL betaL WL Pperm
Two-order interaction models
1 rs11225395 MMP8 × rs1320632 MMP8 1 0.242 2.74 2 − 0.51 10.54 0.008
2 rs1320632 MMP8 × rs11568818 MMP7 0 NA NA 3 − 0.55 10.77 0.010
Three-order interaction models
3 rs1320632 MMP8 × rs11568818 MMP7 × rs3025058 MMP3 1 0.922 3.36 5 − 0.907 23.88 0.002
4 rs11225395 MMP8 × rs1320632 MMP8 × rs11568818 MMP7 1 0.497 4.09 3 − 0.715 16.88 0.004
5 rs17577 MMP9 × rs1320632 MMP8 × rs11568818 MMP7 0 NA NA 2 − 0.927 16.22 0.004
6 rs1320632 MMP8 × rs11568818 MMP7 × rs1799750 MMP1 0 NA NA 3 − 0.816 15.66 0.006
7 rs11225395 MMP8 × rs1320632 MMP8 × rs3025058 MMP3 2 0.460 9.72 4 − 0.634 16.13 0.012
Four-order interaction models
8 rs652438 MMP12 × rs11225395 MMP8 × rs1320632 MMP8 rs11568818 MMP7 1 0.363 3.33 4 − 0.862 23.48 0.002
9 rs652438 MMP12 × rs1320632 MMP8 × rs11568818 MMP7 × rs3025058 MMP3 0 NA NA 5 − 0.918 22.06 0.004
10 rs1320632 MMP8 × rs11568818 MMP7 × rs3025058 MMP3 × rs243865 MMP2 2 0.794 7.05 5 − 1.311 26.38 0.006
11 rs11225395 MMP8 × rs1320632 MMP8 × rs11568818 MMP7 × rs243865 MMP2 2 1.089 7.96 4 − 1.090 23.26 0.006
12 rs17577 MMP9 × rs1320632 MMP8 × rs11568818 MMP7 × rs1799750 MMP1 0 NA NA 4 − 1.261 21.38 0.018
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Expression QTLs.  According to the GTExportal database, four EH-associated SNPs had the cis-eQTL signifi-
cance (p < 8 ×  10–5, pFDR ≤ 0.05) and might affect the expression of five genes (MMP7, MMP27, RP11‑817J15.3, 
SNX21, SLC12A5) in several tissues and organs (Supplementary Table 5). Six EH-associated loci were in strong 
LD with the SNPs affecting the expression (p < 8.5 ×  10–5, FDR ≤ 0.05) of 11 genes in more than 20 tissues and 
organs, including those pathogenetically significant for the development of EH (whole blood, tibial artery, left 
ventricle of heart, etc.) (Supplementary Table 6).
Pathway analyses. The in silico analysis of the functional significance was conducted for the 7 EH-associated 
genes (MMP7, MMP8, MMP1, MMP2, MMP3, MMP9, MMP12) and for genes whose expression is affected by 
the EH-associated SNPs according to the eQTL analysis (Supplementary Tables 5 and 6).
Of the 15 genes considered, the Gene Ontology databases have the relevant information about 12 genes; the 
information about three genes (RP11‑817J15, WTAPP1, and RPL13P2) was not available. We found evidence 
Table 5.  Cross-validation statistics for best models of the gene–gene interactions in EH. Models are obtained 
using the multifactor dimensionality reduction method, version 3.0.2 CI, confidence interval, OR, odds ratio, 
Pperm, permutation P-value for the interaction model.
N SNP × SNP interaction models OR (95% CI) Testing balanced accuracy Cross-validation consistency Pperm
Two-order interaction models
1 rs11225395 MMP8 × rs1320632 MMP8 1.57 (1.23–1.99) 0.543 10/10 0.008
2 rs1320632 MMP8 × rs11568818 MMP7 1.49 (1.16–1.92) 0.537 10/10 0.01
Three-order interaction models
3 rs1320632 MMP8 × rs11568818 MMP7 × rs3025058 MMP3 1.54 (1.22–1.94) 0.511 10/10 0.002
4 rs11225395 MMP8 × rs1320632 MMP8 × rs11568818 MMP7 1.70 (1.35–2.15) 0.540 10/10 0.004
5 rs17577 MMP9 × rs1320632 MMP8 × rs11568818 MMP7 1.72 (1.34–2.22) 0.531 10/10 0.004
6 rs1320632 MMP8 × rs11568818 MMP7 × rs1799750 MMP1 1.51 (1.19–1.91) 0.492 10/10 0.006
7 rs11225395 MMP8 × rs1320632 MMP8 × rs3025058 MMP3 1.73 (1.38–2.17) 0.553 10/10 0.012
Four-order interaction models
8 rs652438 MMP12 × rs11225395 MMP8 × rs1320632 MMP8 rs11568818 MMP7 1.75 (1.40–2.20) 0.537 10/10 0.002
9 rs652438 MMP12 × rs1320632 MMP8 × rs11568818 MMP7 × rs3025058 MMP3 1.71 (1.37–2.14) 0.529 10/10 0.004
10 rs1320632 MMP8 × rs11568818 MMP7 × rs3025058 MMP3 × rs243865 MMP2 1.78 (1.40–2.23) 0.503 10/10 0.006
11 rs11225395 MMP8 × rs1320632 MMP8 × rs11568818 MMP7 × rs243865 MMP2 1.93 (1.54–2.41) 0.531 10/10 0.006
12 rs17577 MMP9 × rs1320632 MMP8 × rs11568818 MMP7 × rs1799750 MMP1 1.73 (1.38–2.16) 0.492 10/10 0.018
Figure 1.  High-order gene–gene interaction analysis for SNPs of matrix metalloproteinases in EH (data 
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of enrichment for pathways involved in the metalloendopeptidase activity  (PFDR = 1.37E−16), collagen cata-
bolic process  (PFDR = 4.68E−15), collagen degradation  (PFDR = 8.92E−15), extracellular matrix disassembly 
 (PFDR = 4.79E−14), activation of matrix metalloproteinases  (PFDR = 2.28E−13), and 10 other pathways (FDR ≤ 0.05) 
(Supplementary Table 7).
The network of the intergenic interactions between the 15 EH-associated genes and other 20 genes inferred 
by GeneMANIA is given in Fig. 2. These interactions are realized through common protein domains (47.03%), 
co-expression (35.73%), pathogenetic pathways (6.11%), co-localization (2.63%), and genetic interactions 
(0.53%). The EH-associated genes may interact either directly or via other genes (e.g., NOP56, NOP58, MMP10, 
MMP21, MMP28, etc.). Among the 35 candidate genes for EH, the most significant interactions were deter-
mined for NOP56 and NOP58 (common protein domains, weight = 0.65), PRPF31 и NOP56 (common protein 
domains, weight = 0.41), PRPF31 и NOP58 (common protein domains, weight = 0.41), MMP7 и MMP3 (path-
ways, weight = 0.10).
Discussion
The present study determined significant associations of eight loci of matrix metalloproteinase genes with EH 
in a Caucasian population of Central Russia.
Allele G of locus rs11568818 MMP7 was associated with EH according to the dominant, additive and recessive 
models (OR = 0.58–0.70) and was involved in 10 of 12 two-, three-, and four-locus models of gene–gene interac-
tions associated with EH. Marker rs11568818 was characterized by a significant regulatory effect: it was located in 
the region hypersensitive to DNAse-1 in 15 tissues, in the region of modified histones (H3K4me1 and H3K4me3) 
that marked promoter and enhancer in 11 different organs and tissues, and affected the MMP7 gene expression. 
The locus was located in the region of DNA that binds to the TATA-binding protein (TBP), c-FOS, c-Jun, and 
located in regulatory protein binding sites. According to the GeneCards database, TBP is responsible for proper 
RNA polymerase positioning on a promoter during transcription; regulatory proteins c-FOS and c-Jun interact 
with each other and control cell proliferation, differentiation, and transformation. The data about the possible 
contribution of rs11568818 to cardiovascular disease in different ethnic populations was somewhat inconsist-
ent. For example, Jormsjö et al.23 showed that carriers of genotype GG rs11568818 MMP7 had an increased risk 
for developing cardiovascular pathology in the Swedish population, while in populations from India, Mexico, 
and Turkey associations of this marker with EH and its complications were not  determined28,30,31. The observed 
inconsistencies could stem from the differences in study designs (e.g., differences in the used covariates, sample 
sizes, gene–gene and gene-environment interactions, etc.). In addition, the differences in the results might be 
Figure 2.  The interaction network of the candidate genes for EH obtained using the GeneMANIA online 
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associated with ethnicity-specific pathogenetic features of the emergence and course of  EH32–37 or/and ethnicity-
related differences in the genetic structure of the  populations38,39.
According to the GeneCards database (http://www.genec ards.org/), the MMP7 gene belongs to the gene 
cluster on chromosome 11 and encodes the enzyme of the same name, which is characterized by the absence 
of a conserved C-terminal hemopexin domain. Matrix metalloproteinase 7 is responsible for proteolytic cleav-
age of elastin, type I, III, IV, V gelatins, fibronectin, casein, proteoglycans and is involved in the regeneration 
processes after damage, remodeling of the extracellular matrix, and also modulates cell migration, proliferation, 
and  apoptosis15.
We did not determine monolocus effects for rs1320632 of the MMP8 gene; however, this marker is involved 
in all 12 identified gene–gene interactions models associated with EH. SNP rs1320632 has significant regulatory 
potential—it is located in the region of DNA regulatory motifs and modulates affinity for seven transcription 
factors (CAC-binding-protein, Foxc1-2, GATA-known13, GCM, MAZ, PRDM1-known1, STAT-disc6). In addi-
tion, this SNP is located in the region of hypersensitivity to DNAse-1 in 10 tissues, in the region of H3K4me1 
and H3K4me3, marking enhancers and promoters in six tissues. We found that rs1320632 MMP8 is strongly 
linked to 14 SNPs that have important regulatory significance, and this locus is associated with a level of the 
MMP27 gene expression in four tissues. Our results are consistent with those previously reported for the Serbian 
 population22. The MMP8 gene encodes a proteolytic enzyme involved in the cleavage of the extracellular matrix 
in the proliferation and remodeling of tissues, embryonic development, as well as in pathological processes such 
as arthritis and metastasis. Selective proteolysis of the polypeptide leads to the formation of many active forms of 
the enzyme with different N-ends. MMP8 is involved in the degradation of type I-III collagen and is expressed 
by macrophages, while the production of MMP8 sharply increases with inflammation.
It should be noted that the current study is somewhat limited because: (a) only one ethnic population was ana-
lyzed. The well-known ethnic disparities in the prevalence of complex diseases warrant validation studies of the 
determined associations of the MMP genes and EH in other ethnic populations; (b) a transethnic meta-analysis 
of the studied MMP SNPs would help to clarify this issue, but is currently impossible due to the insufficient data 
available about MMP and EH; (c) the obtained results are not sufficient to construct a reliable predictive model 
of EH based on the eight studied SNPs using the multi-model deep learning method.
Conclusions
Thus, in this work, we found that genetic polymorphism rs11568818 MMP7 and gene–gene interactions of eight 
SNPs are associated with EH in a Caucasian population of Central Russia, and their phenotypic effects are real-
ized through non-synonymous substitutions, regulatory and cis-eQTL effects, and shaed biological pathways.
Materials and methods
Study subjects. The study sample included 1405 people: 939 patients with essential hypertension and 466 
controls. The participants were recruited through the cardiological and neurological departments of the St. 
Joasaph Belgorod Regional Clinical Hospital during 2013–2016. The following inclusion criteria were adopted: 
self-declared Russian descent, a birthplace in Central  Russia40.
Essential hypertension was diagnosed by certified physicians in cardiology and neurology as recommended 
by the World Health Organization (n = 939, 100%). All study subjects had a clinical history of hypertension for 
more than one year. Untreated hypertensive patients had the established hypertension defined by seated sys-
tolic (SBP) and/or diastolic (DBP) blood pressure above 140 and/or 90 mm Hg, respectively, measured at least 
twice. All hypertensive patients had no clinical signs, symptoms, and laboratory findings suggesting secondary 
hypertension, and liver or/and kidney failure. The controls were recruited during regular medical examinations 
at the above Center. The criterion for inclusion in the control group was the level of SBP < 140 mmHg and the 
level of DBP < 90 mmHg, no history of metabolic syndrome, autoimmune disorders, and oncological diseases.
The level of blood pressure (BP) was determined by the auscultation method using a sphygmomanometer 
and according to  Korotkov41. BP was measured throughout several days (at least twice). The patients had not 
consumed caffeine, exercise, and smoke for at least 30 min before the measurement procedure bean. The measure-
ment was performed in the seated position of the patient after 5 min of rest. The blood pressure was measured 
on both arms: at least two measurements were taken with an interval of 1–2 min. A mean of at least two readings 
taken at least two times was used to assess individual blood pressure.
The study was carried out in accordance with the standards of Good Clinical Practice and the principles of the 
Helsinki Declaration. The study was approved by the Regional Ethics Committee of Belgorod State University. 
All participants signed informed consent before the enrolment in the study.
Data on anthropometric characteristics (height, weight, and body mass index), smoking and alcohol use 
were collected for each participant. Blood samples for determining total cholesterol (TC, mmol/l), triglycerides 
(TG, mmol/l), high-density lipoprotein cholesterol (HDL-C, mmol/l), and low-density lipoprotein cholesterol 
(LDL-C, mmol/l) were collected after 8-h fasting, the analysis was performed in the certified clinical diagnostic 
laboratory of the St. Joasaph Belgorod Regional Clinical Hospital. The baseline and clinical characteristics of the 
study population are given in Table 1. The control group was matched to the EH group for sex and age (p > 0.05).
SNP selection and DNA handling. DNA was extracted from whole blood by the phenol–chloroform 
protocol and then checked for quality (as described  earlier42).
Eight single nucleotide polymorphisms (SNPs) of seven matrix metalloproteinase genes (rs1799750 MMP1, 
rs243865 MMP2, rs3025058 MMP3, rs11568818 MMP7, rs1320632 and rs11225395 MMP8, rs17577 MMP9, 
and rs652438 MMP12) were selected for the study based on the following  criteria42,43: (1) SNP associations with 
the development of EH and/or its complications according to the results of previous studies; (2) the regulatory 
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effect of a polymorphism (regSNP); (3) the effect of the locus on gene expression (eSNP); (4) relation to non-
synonymous substitutions (nsSNP); (5) MAF > 0.05. The SNPs regulatory potential and effect on the gene 
expression were assessed using HaploReg (v4.1) (http://archi ve.broad insti tute.org/mamma ls/haplo reg/haplo 
reg.php), SNPinfo Web Server—SNP Function Prediction (FuncPred) (https ://snpin fo.niehs .nih.gov/snpin fo/
snpfu nc.html), and GTExportal (http://www.gtexp ortal .org/).
Information on the biological role of the studied polymorphisms and their associations with cardiovascular 
pathology is presented in Supplementary Table 8. All SNPs appeared to have significant regulatory potential, 
four of them (50.00%) were eSNPs, and 2 were nsSNPs (Supplementary Table 3).
SNP genotyping. The polymorphisms were genotyped using the MALDI‐TOF mass spectrometry iPLEX 
platform (Agena Bioscience Inc, San Diego, CA). Genotyping of blind replicates was performed to ensure quality 
control. The repeatability test was performed for 5% of randomly selected samples and showed 100% reproduc-
ibility.
Statistical analysis. Correspondence of the studied loci to the Hardy–Weinberg equilibrium (HWE) was 
checked by the chi-square test. The loci were analyzed for associations with EH using logistic regression and 
according to additive (i.e., comparison of all genotypes, e.g., TT vs TC vs CC), dominant (CC/TC vs TT, where 
C is a minor allele), and recessive (CC vs TC/TT, where C is a minor allele) genetic models with adjustment for 
covariates. The following covariates were applied as quantitative variables: BMI, total cholesterol, triglycerides, 
high-density and low-density lipoprotein cholesterol; and while smoking status was used as qualitative variables 
(yes/no) (Table 1). The adaptive permutation  test44 was applied to adjust the results for multiple comparisons. 
The significance level was set at pperm < 0.05. The calculations were performed using software PLINK v.2.050 
(http://zzz.bwh.harva rd.edu/plink /). Statistical power for each SNP was estimated using Quanto 1.2.4 (http://
hydra .usc.edu/gxe, 2009).
The epistatic interactions were analyzed assuming two-, three-, and four-locus models. The MB-MDR (Model 
Based Multifactor Dimensionality Reduction)45,46 approach and respective software (v. 2.6) for the R program-
ming environment were utilized for the computations. The significance of the gene–gene interaction models 
was evaluated by the permutation  test44. For the permutation test, the following threshold p values (after the 
Bonferroni correction based on the numbers of combinations studied for eight loci) were adopted for the models 
of the gene–gene interactions: p < 1.8 ×  10–3 (< 0.05/28) for the two-locus models, p < 8.9 ×  10–4 (< 0.05/56) for 
the three-locus models, and p < 7.1 ×  10–4 (< 0.05/70) for the four-locus models. The significance level was set 
at pperm < 0.05.
The cross-validation of the most significant models of intergenic interactions associated with EH was con-
ducted by MDR (Multifactor Dimensionality Reduction)47, as implemented in the MDR software (v.3.0.2) (http://
sourc eforg e.net/proje cts/mdr). The MDR method was used to assess the nature and strength (contribution to 
entropy) of gene–gene interactions and visualize them in graph  form48.
Functional SNPs. The SNPs associated with EH and those strongly linked to them were evaluated for their 
functional significance (non-synonymous  SNPs49, regulatory  potential50,51, and  eQTLs52). The loci in linkage 
disequilibrium (LD)  (r2 ≥ 0.8) with the EH-associated ones were determined using HaploReg (v4.1) (http://archi 
ve.broad insti tute.org/mamma ls/haplo reg/haplo reg.php) and the data of the European population from the 1000 
Genomes Project Phase  142,50,53,54.
Non‑synonymous SNPs. Non-synonymous SNPs and their predictive potential were analyzed using the SIFT 
tool (https ://sift.bii.a-star.edu.sg/)49.
Regulatory effects. The candidate loci for EH were analyzed in silico for their regulatory potential using Hap-
loReg (v4.1) (http://archi ve.broad insti tute.org/mamma ls/haplo reg/haplo reg.php)50 and SNP Function Predic-
tion (FuncPred) (https ://snpin fo.niehs .nih.gov/snpin fo/snpfu nc.html)51.
Expression QTLs. The effect of the candidate SNPs for EH on gene expression in various tissues and organs 
was estimated using the GTExportal data (http://www.gtexp ortal .org/) as of 10.12.2019 (Release V8 updated 
on 26/08/2019) (dbGaP Accession phs000424.v8.p2)52. The False Discovery Rate (FDR) ≤ 0.05 was applied as 
statistical significance  threshold55.
Pathway analyses. The genes associated with EH were analyzed for functional significance in the various meta-
bolic pathways using the Gene Ontology Portal (PANTHER Overrepresentation Test accessed on 13.04.2017; 
PANTHER version 12.0 accessed on 10.07.2017, http://geneo ntolo gy.org)56. The adjustment for multiple com-
parisons was made using the FDR test. The networks of intergene interaction were inferred using GeneMANIA 
(version 3.5.0, accessed on 13 March 2017, http://genem ania.org) and the automatic weighting for the  network57.
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